
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5681202/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	HPV Vaccination and the Risk of Invasive Cervical Cancer. New England Journal of Medicine, 2020, 383, 1340-1348.	27.0	723
2	Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other Demyelinating Diseases of the Central Nervous System. JAMA - Journal of the American Medical Association, 2015, 313, 54.	7.4	141
3	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nature Reviews Clinical Oncology, 2018, 15, 292-309.	27.6	129
4	Quadrivalent <scp>HPV</scp> vaccine effectiveness against highâ€grade cervical lesions by age at vaccination: A populationâ€based study. International Journal of Cancer, 2016, 138, 2867-2874.	5.1	108
5	Attitudes to HPV vaccination among parents of children aged 12â€15 years—A populationâ€based survey in Sweden. International Journal of Cancer, 2010, 126, 500-507.	5.1	94
6	Prospective Study of Human Papillomavirus (HPV) Types, HPV Persistence, and Risk of Squamous Cell Carcinoma of the Cervix. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2469-2478.	2.5	56
7	High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study. PLoS Medicine, 2018, 15, e1002666.	8.4	55
8	Prospective study of human papillomavirus and risk of cervical adenocarcinoma. International Journal of Cancer, 2010, 127, 1923-1930.	5.1	54
9	Incidence of herpes zoster and associated events including stroke—a population-based cohort study. BMC Infectious Diseases, 2015, 15, 488.	2.9	53
10	Assessing Perceived Risk and STI Prevention Behavior: A National Population-Based Study with Special Reference to HPV. PLoS ONE, 2011, 6, e20624.	2.5	44
11	Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer. British Journal of Cancer, 2018, 118, 1377-1381.	6.4	43
12	Acceptability of HPV vaccination among young adults aged 18–30 years–a population based survey in Sweden. Vaccine, 2010, 28, 7492-7500.	3.8	40
13	Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study. BMJ, The, 2016, 352, i276.	6.0	40
14	Prospective Study of HPV16 Viral Load and Risk of <i>In Situ</i> and Invasive Squamous Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 150-158.	2.5	38
15	Incomplete excision of cervical intraepithelial neoplasia as a predictor of the risk of recurrent disease—a 16-year follow-up study. American Journal of Obstetrics and Gynecology, 2020, 222, 172.e1-172.e12.	1.3	38
16	Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden. PLoS Medicine, 2017, 14, e1002414.	8.4	37
17	The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study. PLoS ONE, 2015, 10, e0134185.	2.5	36
18	Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR. British Journal of Cancer, 2020, 123, 1790-1795.	6.4	36

#	Article	IF	CITATIONS
19	Advances in cervical cancer prevention: Efficacy, effectiveness, elimination?. PLoS Medicine, 2020, 17, e1003035.	8.4	36
20	Interactions Between High- and Low-Risk HPV Types Reduce the Risk of Squamous Cervical Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	33
21	Incidence of newâ€onset autoimmune disease in girls and women with preâ€existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study. Journal of Internal Medicine, 2016, 280, 618-626.	6.0	33
22	Psychologic Distress Is Associated with Cancer-Specific Mortality among Patients with Cervical Cancer. Cancer Research, 2019, 79, 3965-3972.	0.9	33
23	Loss of a parent and the risk of cancer in early life: a nationwide cohort study. Cancer Causes and Control, 2014, 25, 499-506.	1.8	32
24	Increasing participation in cervical screening by targeting longâ€ŧerm nonattenders: Randomized health services study. International Journal of Cancer, 2019, 145, 3033-3039.	5.1	32
25	Cervical cancer case–control audit: Results from routine evaluation of a nationwide cervical screening program. International Journal of Cancer, 2020, 146, 1230-1240.	5.1	32
26	Mode of HPV vaccination delivery and equity in vaccine uptake: A nationwide cohort study. Preventive Medicine, 2019, 120, 26-33.	3.4	30
27	Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples. Journal of Clinical Virology, 2016, 80, 36-39.	3.1	26
28	Barriers to and Facilitators of Compliance with Clinic-Based Cervical Cancer Screening: Population-Based Cohort Study of Women Aged 23-60 Years. PLoS ONE, 2015, 10, e0128270.	2.5	25
29	Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up. Human Vaccines and Immunotherapeutics, 2021, 17, 943-949.	3.3	24
30	Bereavement Is Associated with an Increased Risk of HPV Infection and Cervical Cancer: An Epidemiological Study in Sweden. Cancer Research, 2016, 76, 643-651.	0.9	23
31	Awareness and Knowledge of Human Papillomavirus in the Swedish Adult Population. Journal of Adolescent Health, 2012, 50, 204-206.	2.5	22
32	The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nature Communications, 2022, 13, 449.	12.8	21
33	Human Papillomavirus Infection Determines Prognosis in Cervical Cancer. Journal of Clinical Oncology, 2022, 40, 1522-1528.	1.6	20
34	Follow-up of women with cervical cytological abnormalities showing atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion:Âa nationwide cohort study. American Journal of Obstetrics and Gynecology, 2017, 216, 48.e1-48.e15.	1.3	19
35	Opportunistic HPV vaccination at age 16–23 and cervical screening attendance in Sweden: a national register-based cohort study. BMJ Open, 2018, 8, e024477.	1.9	19
36	How Many Human Papillomavirus Types Do We Need to Screen For?. Journal of Infectious Diseases, 2021, 223, 1510-1511.	4.0	19

#	Article	IF	CITATIONS
37	Using machine learning for predicting cervical cancer from Swedish electronic health records by mining hierarchical representations. PLoS ONE, 2020, 15, e0237911.	2.5	18
38	Differing Age-Specific Cervical Cancer Incidence Between Different Types of Human Papillomavirus: Implications for Predicting the Impact of Elimination Programs. American Journal of Epidemiology, 2021, 190, 506-514.	3.4	18
39	Laboratory audit as part of the quality assessment of a primary HPV-screening program. Journal of Clinical Virology, 2016, 75, 33-36.	3.1	17
40	Sequencing detects human papillomavirus in some apparently HPV-negative invasive cervical cancers. Journal of General Virology, 2020, 101, 265-270.	2.9	16
41	Mothers' acceptance of human papillomavirus (HPV) vaccination for daughters in a country with a high prevalence of HPV. Oncology Reports, 2015, 33, 2521-2528.	2.6	14
42	Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study. British Journal of Cancer, 2018, 119, 1163-1168.	6.4	14
43	Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination. Current Opinion in Oncology, 2014, 26, 120-129.	2.4	13
44	What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries. BMJ Open, 2018, 8, e023789.	1.9	13
45	Risk stratification in cervical cancer screening by complete screening history: Applying bioinformatics to a general screening population. International Journal of Cancer, 2017, 141, 200-209.	5.1	12
46	Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study. BMJ Open, 2017, 7, e015021.	1.9	11
47	Human Papillomavirus Detection by Whole-Genome Next-Generation Sequencing: Importance of Validation and Quality Assurance Procedures. Viruses, 2021, 13, 1323.	3.3	11
48	Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening. BMC Cancer, 2020, 20, 396.	2.6	9
49	Organized primary human papillomavirus–based cervical screening: A randomized healthcare policy trial. PLoS Medicine, 2021, 18, e1003748.	8.4	9
50	Comparison of DNA and RNA sequencing of total nucleic acids from human cervix for metagenomics. Scientific Reports, 2021, 11, 18852.	3.3	9
51	Differential uptake of herpes zoster vaccination associated with socioeconomic status: A populationâ€based study in Stockholm County, Sweden. Pharmacoepidemiology and Drug Safety, 2018, 27, 1159-1165.	1.9	8
52	The HPV16 Genome Is Stable in Women Who Progress to <i>In Situ</i> or Invasive Cervical Cancer: A Prospective Population-Based Study. Cancer Research, 2019, 79, 4532-4538.	0.9	8
53	Cervical screening in high-income countries: the need for quality assurance, adjunct biomarkers and rational adaptation to HPV vaccination. Preventive Medicine, 2021, 144, 106382.	3.4	8
54	Emergency contraceptive pill use among women in Denmark, Norway and Sweden: Populationâ€based survey. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 1214-1221.	2.8	6

#	Article	IF	CITATIONS
55	Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources. Expert Review of Vaccines, 2022, 21, 227-240.	4.4	6
56	Sexually transmitted infections after bereavement – a population-based cohort study. BMC Infectious Diseases, 2016, 16, 419.	2.9	5
57	Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study. PLoS ONE, 2016, 11, e0156215.	2.5	5
58	Finding Cervical Cancer Symptoms in Swedish Clinical Text using a Machine Learning Approach and NegEx. AMIA Annual Symposium proceedings, 2015, 2015, 1296-305.	0.2	5
59	Acceptance of human papillomavirus (HPV) vaccination among young women in a country with a high prevalence of HPV infection. International Journal of Oncology, 2013, 43, 1310-1318.	3.3	3
60	Use of real-world data for HPV vaccine trial follow-up in the Nordic region. Contemporary Clinical Trials, 2020, 92, 105996.	1.8	3
61	Validation of the cobas 6800 human papillomavirus test in primary cervical screening. PLoS ONE, 2021, 16, e0247291.	2.5	3
62	More evidence suggesting that 1â€dose human papillomavirus vaccination may be effective. Cancer, 2020, 126, 1602-1604.	4.1	2
63	Authors' response: Letter to the Editor – <scp>HPV</scp> vaccine and autoimmunity. Journal of Internal Medicine, 2017, 281, 311-312.	6.0	1
64	Stratifying Cervical Cancer Risk with Registry Data. , 2018, , .		1
65	Reply to Ryser et al International Journal of Cancer, 2017, 141, 416-418.	5.1	О